Name: how bacteria outsmart antibiotics
Uploaded: 2026-03-12T13:35:59.000Z
Duration: 1 min 25 s
Channel: JoVE

Staphylococcus aureus jest powszechnie występujący na ludzkiej skórze, ale jest oportunistycznym patogenem.Gronkowec oporny na metycylinę, czyli MRSA, to rodzaj S. aureus oporny na metycylinę oraz większość innych antybiotyków β-laktamowych, takich jak penicylina.Szczepy MRSA zmieniają białka wiążące penicylinę, czyli PBP, które są celem większości β-laktamów.W szczepach MRSA ta oporność rozwija się dzięki obecności genu mecA , który koduje zmienione białko wiążące penicylinę znane jako PBP2a.Ten zmieniony PBP2a ma niskie wiążenie do antybiotyków beta-laktamowych, co pozwala MRSA syntetyzować ścianę komórkową nawet w obecności tych leków.W wielu szczepach MRSA geny regulacyjne mecI i mecR1 kontrolujące ekspresję mecA są niefunkcjonalne.Skutkuje to ciągłą ekspresją PBP2a oraz rozwojem stabilnej oporności.MRSA może wykazywać odporność heterogeniczną, gdzie tylko część populacji bakteryjnej wykazuje oporność, lub jednorodną oporność, w której cała populacja jest odporna.

mechanizm oporności na antybiotyki w mrsa

Mechanism of Antibiotic Resistance in MRSA

Oporność na antybiotyki u bakterii powstaje, gdy mikroorganizmy wykształcają zdolność do wytrzymania leków mających na celu ich zabijanie lub hamowanie wzrostu, co czyni kiedyś skuteczne leczenie bezużytecznym. To zjawisko, wywołane zmianami genetycznymi i selekcją pod wpływem ekspozycji na antybiotyki, stanowi poważne zagrożenie dla współczesnej medycyny. Mechanizmy obejmują enzymy inaktywujące leki (np. β-laktamazy), pompy wypływające antybiotyki, mutacje zmieniające cele antybiotyków, zmniejszone pobieranie leków oraz nabycie genów oporności poprzez poziomy transfer genów. Oporność może rozwijać się de novo poprzez mutację lub być szybko rozprzestrzeniana przez mobilne elementy genetyczne, takie jak plazmidy i transpozony. Presja selekcyjna wynikająca z nadużywania i nadmiernego stosowania antybiotyków przyspiesza powstawanie i rozprzestrzenianie się szczepów opornych.Klinicznie infekcje oporne na antybiotyki są trudniejsze do leczenia, często wymagają bardziej toksycznych lub droższych leków, wydłużają pobyt w szpitalu, podnoszą koszty opieki zdrowotnej oraz zwiększają zachorowalność i śmiertelność. Globalne szacunki ostrzegają przed milionami zgonów rocznie, jeśli trendy oporu się utrzymają.Gronkowec aureus oporny na metycylinę (MRSA) MRSA to paradygmat oporności na antybiotyki. Poprzez pozyskanie genu mecA przez pierwiastek SCCmec, S. aureus wytwarza zmienione białko wiążące penicylinę PBP2a, które nie wiąże się z lekami β-laktamowymi, co zapewnia szeroką odporność na penicyliny, cefalosporyny i karbapenemy. MRSA pojawiła się w szpitalach (HA-MRSA), a później w społecznościach (CA-MRSA), napędzana zarówno mutacjami, jak i poziomym transferem genów. Klinicznie MRSA powoduje poważne zakażenia skóry, tkanek miękkich, krwi oraz zapalenia płuc, często leczone wankomycyną, daptomycyną lub linezolidem, choć te alternatywy mają ograniczenia.Inne przykłady oporności na antybiotyki u bakterii:Enterokoki oporne na wankomycynę (VRE) i VRSA Enterokoki oporne na wankomycynę powstały w wyniku nabycia operonów gena van gena (np. vanA). Te geny przeniosły się dalej do S. aureus, co skutkuje powstaniem rzadkich, lecz niebezpiecznych szczepów S. aureus (VRSA) opornych na wankomycynę. Zakażenia VRSA są trudne do leczenia ze względu na ograniczone alternatywy i stanowią poważne obawy kliniczne, mimo że są rzadkie.Lekooporny Streptococcus pneumoniae (DRSP) S. pneumoniae rozwinęła odporność na penicylinę poprzez mutacje białek wiążących penicylinę oraz makrolidów za pośrednictwem genów metylotransferazy. Te zmiany zmniejszyły skuteczność leczenia zapalenia płuc, zapalenia opon mózgowych i zapalenia ucha środkowego, co wymaga stosowania wyższych stopni antybiotyków, takich jak cefalosporyny czy fluorochinolony, które niosą ze sobą ryzyko.Podsumowując, oporność na antybiotyki ewoluuje poprzez adaptację genetyczną i wymianę genów, z istotnym wpływem klinicznym na kluczowe patogeny, takie jak MRSA, VRE/VRSA i DRSP. Zapewnienie odpowiedniego stosowania antybiotyków, monitorowanie wzorców oporności, kontrola zakażeń oraz opracowanie nowych terapii pozostają niezbędne, aby złagodzić ten narastający kryzys zdrowia publicznego.

Mechanizm oporności na antybiotyki w MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, ...

https://cloudfront.jove.com/files/ftp_upload/40835/40835_article_thumb_40835.jpg

mechanism-of-antibiotic-resistance-in-mrsa

Education

JoVE Core

Microbiology

Mikrobiologia

Unit

Jednostka

Antimicrobial Agents

Środki przeciwdrobnoustrojowe

KEY TERMS AND CONCEPTS

KLUCZOWE TERMINY I POJĘCIA

how bacteria outsmart antibiotics

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working.

Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower drug uptake, or from new resistance genes gained through horizontal gene transfer, which is the movement of DNA between organisms.

Resistance may appear through new mutations or spread quickly through mobile genetic elements like plasmids and transposons. Misuse and overuse of antibiotics increase selection pressure, which helps resistant strains survive and spread. This makes antibiotic-resistant infections harder to treat and often forces doctors to use more toxic or more expensive drugs. These infections can also lead to longer hospital stays, higher healthcare costs, and more illness and death.

MRSA, short for methicillin-resistant Staphylococcus aureus, is a well-known example of this process. It acquired the mecA gene through the SCCmec element and makes an altered penicillin-binding protein called PBP2a. Because PBP2a does not bind beta-lactam drugs well, MRSA resists penicillins, cephalosporins, and carbapenems. MRSA first spread in hospitals as HA-MRSA and later in communities as CA-MRSA. It can cause skin, soft-tissue, bloodstream, and pneumonia infections, and it is often treated with vancomycin, daptomycin, or linezolid, although these options have limits.

Other resistant bacteria show the same problem in different forms. Vancomycin-resistant enterococci can gain van genes, such as vanA, and those genes can transfer to S. aureus to create rare but dangerous VRSA strains. Streptococcus pneumoniae can become resistant to penicillin through changes in penicillin-binding proteins and to macrolides through methyltransferase genes. These changes can make pneumonia, meningitis, and otitis media harder to treat and may require higher-tier antibiotics such as cephalosporins or fluoroquinolones.

Antibiotic resistance grows through genetic adaptation and gene exchange. Its impact reaches major pathogens such as MRSA, VRE, VRSA, and drug-resistant S. pneumoniae. Careful antibiotic use, resistance surveillance, infection control, and new treatments are important ways to slow this public health threat.

How Bacteria Outsmart Antibiotics

inhibitors of gram-positive cell wall synthesis

inhibitors-of-gram-positive-cell-wall-synthesis

How Antibiotics Block Bacterial Cell Walls

Bacterial cell walls are rigid structures built mainly from peptidoglycan. This mesh-like polymer gives bacteria strength and helps maintain cell shape. Because peptidoglycan synthesis is essential for growth, it is a major target for antibiotics. Beta-lactam antibiotics, such as penicillin, stop peptidoglycan synthesis in actively growing cells. They have a four-membered beta-lactam ring that mimics the D-alanyl-D-alanine dipeptide, which is the natural substrate for transpeptidase, also...

inhibitors of bacterial protein synthesis

inhibitors-of-bacterial-protein-synthesis

Aminoglycosides: How They Stop Bacteria

Aminoglycosides are bactericidal antibiotics that stop bacteria by targeting the ribosome and disrupting protein synthesis. They are highly potent drugs made of amino-modified sugars linked by glycosidic bonds to an aminocyclitol core, such as 2-deoxystreptamine or streptamine. Their strong positive charge helps them bind tightly to the negatively charged phosphate backbone of ribosomal RNA, especially the 16S rRNA of the 30S subunit in the bacterial 70S ribosome. These antibiotics act at the...

inhibitors of bacterial dna synthesis

Fluoroquinolone Antibiotics and Bacterial DNA

Fluoroquinolone antibiotics target bacterial DNA replication by blocking two key type II topoisomerases: DNA gyrase and topoisomerase IV. These enzymes help bacteria manage DNA supercoiling and separate chromosomes during replication. When they are disrupted, bacterial pathogens cannot copy DNA efficiently and infection can spread less effectively. Fluoroquinolones are synthetic versions of quinolones. They work by stabilizing the short-lived DNA-enzyme cleavage complex, which stops strand...

inhibitors of viral protein synthesis

Interferons Block Viral Replication

Interferons block viral replication by shutting down protein synthesis and activating the cell’s antiviral defenses. Viruses need the host cell’s translational machinery to make proteins, because they do not have the machinery to do this on their own. When a virus is detected, infected cells release interferons, which are cytokines, or signaling proteins, that warn nearby uninfected cells. Interferons bind to receptors on nearby cells and activate the JAK-STAT signaling pathway. This turns on...

inhibitors of virion release

Neuraminidase Inhibitors and Flu Spread

Influenza viruses spread when new virions leave an infected cell and reach nearby cells. Influenza A and B are negative-sense, single-stranded RNA viruses with segmented genomes. They depend on two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), to infect cells, make new viral particles, and release them. HA starts infection by binding to sialic acid on the surface of host epithelial cells. This binding helps the virus enter the cell by receptor-mediated endocytosis. After...

antiviral nucleoside inhibitors

How Antiviral Drugs Stop Viral Replication

Antiviral nucleoside inhibitors stop viruses by blocking DNA or RNA synthesis. These drugs are structural analogs, which means they look like natural nucleosides, the building blocks cells use to make genetic material. Because they resemble host nucleosides, they can interfere with viral polymerases and disrupt viral genome replication. Acyclovir is a guanosine analog with a three-carbon acyclic side chain. It mainly targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2...

antifungal agents

Amphotericin B and Fungal Membranes

Amphotericin B targets fungal cell membranes by binding to ergosterol, a sterol found mainly in fungal plasma membranes. Its amphipathic structure helps this selective binding. It has a hydrophobic polyene-lactone ring and a hydrophilic region with mycosamine and carboxylic acid groups. Weak binding to cholesterol can also affect human cells and helps explain the drug’s toxicity. One way amphotericin B kills fungi is through pore formation. In this model, amphotericin B-ergosterol complexes...

mechanism of antibiotic resistance in mrsa

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working. Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower...

anthelminthic agents

Helminth Drugs and How They Work

Helminth drugs work by attacking the weak points of parasitic worms. These anthelmintic medicines are different from drugs used against protozoa, because they are usually aimed at mature helminths rather than fast-dividing cells. They target the worm’s movement, glucose use, and microtubule structure to stop survival, reproduction, and location inside the host. Benzimidazoles are broad-spectrum anthelmintics that block tubulin polymerization, which means they interfere with microtubules, the...

clinical significance of antibiotic resistance

clinical-significance-of-antibiotic-resistance

MRSA: Host Adaptation and Transmission

MRSA, or methicillin-resistant Staphylococcus aureus, is a major public health threat. It resists beta-lactam antibiotics because it carries the mecA gene inside the staphylococcal cassette chromosome mec, or SCCmec. The mecA gene makes penicillin-binding protein 2a, which reduces how well methicillin and related beta-lactam drugs can bind. MRSA has spread into separate clonal lineages that affect both humans and animals. These lineages fit the One Health idea, which links human, animal, and...

inhibitors of virion maturation and assembly

inhibitors-of-virion-maturation-and-assembly

HIV Protease Inhibitors and Maturation

HIV protease inhibitors block a key step in virus maturation. In human immunodeficiency virus (HIV), infected cells make two long precursor proteins called polyproteins. These are Gag and Gag-Pol. Gag provides the virus structure. Gag-Pol carries important viral enzymes, including reverse transcriptase, integrase, and protease. After these polyproteins are made, they move to the host cell membrane. There, they help build an immature viral particle that buds from the cell surface. Budding...

antiprotozoal agents

Leishmaniasis and Trypanothione Reductase

Leishmaniasis is a parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. Treatment often relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. The way these drugs work has not been fully clear. One important target is trypanothione reductase, or TR, an enzyme that helps keep Leishmania in redox balance. TR is not found in mammalian hosts, so it is a...

key terms and concepts

Learn how bacteria become antibiotic resistant, from beta-lactamases and efflux pumps to MRSA, VRE, VRSA, and drug-resistant Streptococcus pneumoniae.

How Bacteria Outsmart Antibiotics | JoVE K12

JoVE Core Microbiology provides an engaging introduction to the microbial world and its influence on health, industry, and the environment. This comprehensive collection covers key concepts such as microbial structure, metabolism, genetics, and ecology. It introduces essential laboratory techniques and microscopy methods through visually engaging animations. Corresponding scientist-in-action videos bridge classroom concepts with real-world research and applications.

microbiology

How Bacteria Outsmart Antibiotics

Description

Transcript

Tags